Unicycive Therapeutics Inc
UNCY6.180USD
+0.060+0.98%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
128.86MMarket Cap
LossP/E TTM
More Details of Unicycive Therapeutics Inc Company
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Inc Info
Ticker SymbolUNCY
Company nameUnicycive Therapeutics Inc
IPO dateJun 17, 2021
CEOGupta (Shalabh)
Number of employees22
Security typeOrdinary Share
Fiscal year-endJun 17
Address4300 El Camino Real, Suite 210
CityLOS ALTOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94022
Phone16503840642
Websitehttps://unicycive.com/
Ticker SymbolUNCY
IPO dateJun 17, 2021
CEOGupta (Shalabh)
Company Executives of Unicycive Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
8.33%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
The Vanguard Group, Inc.
3.07%
Other
75.88%
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
8.33%
Octagon Capital Advisors LP
4.65%
Nantahala Capital Management, LLC
4.37%
Great Point Partners, LLC
3.71%
The Vanguard Group, Inc.
3.07%
Other
75.88%
Shareholder Types
Shareholders
Proportion
Hedge Fund
14.44%
Venture Capital
10.71%
Investment Advisor
3.40%
Individual Investor
2.93%
Investment Advisor/Hedge Fund
1.54%
Research Firm
0.29%
Other
66.69%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
65
6.53M
30.38%
-306.64K
2025Q3
61
5.54M
31.38%
-1.91M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Vivo Capital, LLC
1.79M
8.33%
+652.90K
+57.42%
Sep 30, 2025
Octagon Capital Advisors LP
1.00M
4.65%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
939.20K
4.37%
--
--
Sep 30, 2025
Great Point Partners, LLC
796.56K
3.71%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
658.88K
3.07%
+52.92K
+8.73%
Sep 30, 2025
Gupta (Shalabh K)
597.25K
2.78%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
2.2%
+1.00
+0.00%
Sep 30, 2025
Rosalind Advisors, Inc.
242.49K
1.13%
+242.49K
--
Apr 30, 2025
Geode Capital Management, L.L.C.
125.73K
0.58%
+66.94K
+113.87%
Sep 30, 2025
Squarepoint Capital LLP
117.33K
0.55%
+117.33K
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 17, 2025
Merger
10→1
Date
Type
Ratio
Jun 17, 2025
Merger
10→1
FAQs
Who are the top five shareholders of Unicycive Therapeutics Inc?
The top five shareholders of Unicycive Therapeutics Inc are:
Vivo Capital, LLC holds 1.79M shares, accounting for 8.33% of the total shares.
Octagon Capital Advisors LP holds 1.00M shares, accounting for 4.65% of the total shares.
Nantahala Capital Management, LLC holds 939.20K shares, accounting for 4.37% of the total shares.
Great Point Partners, LLC holds 796.56K shares, accounting for 3.71% of the total shares.
The Vanguard Group, Inc. holds 658.88K shares, accounting for 3.07% of the total shares.
Vivo Capital, LLC holds 1.79M shares, accounting for 8.33% of the total shares.
Octagon Capital Advisors LP holds 1.00M shares, accounting for 4.65% of the total shares.
Nantahala Capital Management, LLC holds 939.20K shares, accounting for 4.37% of the total shares.
Great Point Partners, LLC holds 796.56K shares, accounting for 3.71% of the total shares.
The Vanguard Group, Inc. holds 658.88K shares, accounting for 3.07% of the total shares.
What are the top three shareholder types of Unicycive Therapeutics Inc?
The top three shareholder types of Unicycive Therapeutics Inc are:
Vivo Capital, LLC
Octagon Capital Advisors LP
Nantahala Capital Management, LLC
Vivo Capital, LLC
Octagon Capital Advisors LP
Nantahala Capital Management, LLC
How many institutions hold shares of Unicycive Therapeutics Inc (UNCY)?
As of 2025Q4, 65 institutions hold shares of Unicycive Therapeutics Inc, with a combined market value of approximately 6.53M, accounting for 30.38% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.00%.
What is the biggest source of revenue for Unicycive Therapeutics Inc?
In --, the -- business generated the highest revenue for Unicycive Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
